Endpoint Clinical buys Bluefin to move into clinical supply planning
What's the deal? Endpoint ClinicalDealroom has a profile for this one. Try Dealroom →, a global provider of randomization and trial supply management (RTSM) solutions, has acquired BluefinDealroom has a profile for this one. Try Dealroom →, a Boston-based maker of clinical supply forecasting and planning technology. The deal was announced on September 14, 2026; terms were not disclosed.
What's the endgame? The acquisition pushes Endpoint into clinical supply chain planning while keeping Bluefin operating independently. Crucially, Bluefin will stay RTSM- and forecasting-agnostic, continuing to connect with rival systems across the industry.
Why now? Clinical supply planning is growing more complex and more tied to real-time trial data. The two companies want to link supply plans to trial execution data so teams can anticipate enrollment shifts and automate forecasting rather than react to them.
Endpoint will back Bluefin with global project management, implementation, quality, and customer support to help sponsors deploy the platform at scale.
What they're saying: "Bluefin gives Endpoint a strong foundation in clinical supply planning while preserving customer choice across RTSM providers," said Nagaraja "Sri" Srivatsan, chief executive officer of Endpoint Clinical.
Bluefin co-founder and chief executive officer Andy Maltun said the fit was obvious: "The connection between RTSM and clinical supply forecasting is so natural that it's one of the first opportunities we discuss with every sponsor."
The backers: Endpoint is a portfolio company of Arsenal Capital PartnersDealroom has a profile for this one. Try Dealroom →, which acquired it in 2024. Mark A. Goldberg, MD, Endpoint's chairman and an Arsenal operating partner, framed the deal as consistent with a strategy of "building technology-rich companies that solve meaningful enterprise problems for healthcare customers."
The signal: The deal reflects a push to consolidate the fragmented clinical trial technology stack, linking planning, forecasting, and execution data into a single intelligence layer. By keeping Bluefin open across any RTSM environment, Endpoint bets that neutrality — not lock-in — is the way to win over sponsors managing increasingly complex global studies.
Image credit: Generated with Gemini
